Hosseinion Warren 4

What Happened
Warren Hosseinion, President and director of Nutex Health, had 6,293 restricted stock units (RSUs) convert into common shares on March 10, 2026 (converted at $0). Of those, 3,274 shares were sold at $86.22 per share to satisfy tax withholding obligations, generating proceeds of about $282,292. Separately, Hosseinion was granted 3,656 new RSUs (see footnote) that vest over three years.

Key Details

• Transaction dates: conversions and tax-withholding sale on 2026-03-10; RSU grant referenced on 2026-03-11.
• Conversion: 6,293 RSUs converted to common stock (code M, $0 exercise price; footnote F1: 1-for-1 conversion).
• Sale for taxes: 3,274 shares disposed (code F) at $86.22 each = $282,292 (footnote F2: sold to cover tax withholding).
• Grant: 3,656 RSUs granted (footnote F3) vesting in three equal installments on 3/1/2027, 3/1/2028, and 3/1/2029.
• Shares owned after the transactions: not specified in the filing.
• Filing: Form 4 filed 2026-03-11 (appears timely relative to the reported transactions).

Context
This was primarily an RSU conversion and a routine sell-to-cover for tax withholding, not a market-speculative sale. The converted RSUs had no cash exercise cost (typical for RSU vest/conversion). The new RSU grant vests over three years, so those shares are not yet vested common stock. Purchases would typically be a stronger bullish signal; this filing reflects standard compensation-related activity.